Long-term GH replacement in our study was associated with lower CV risk in both MPHD and presumed IGHD patients, which further underlines the need for GH replacement therapy in patients with MPHD and adds to available evidence suggesting the importance of GH replacement in these patients (22, 23, 24). This evidence concerns the gene GH1 and isolated congenital growth hormone deficiency.